Table 5

Summary of STEP results11–15

Trial (n)Doses and comparatorsEstimated mean weight change (%)Patients with weight loss of:>5%,>10%,>15% (%)Body weight change from baseline (kg)
STEP 1 (n=1961)11SC semaglutide 2.4 mg−14.986.4, 69.1, 50.5−15.3
Placebo−2.431.5, 12.0, 4.9−2.6
STEP 2 (n=1210)12SC semaglutide 2.4 mg−9.668.8,45.6, 25.8−9.7
SC semaglutide 1.0 mg−7.057.1, 28.7, 13.7,−2.5
Placebo−3.428.5, 8.2, 3.2−1.3
STEP 3 (n=611)13SC semaglutide 2.4 mg−1686.6, 75.3, 55.8−16.8
Placebo (+intensive behavioral therapy)−5.747.6, 27, 13.2−6.2
STEP 4 (n=902)14SC semaglutide (68 total weeks)−7.9NR−7.1
SC semaglutide (20 weeks), then placebo (48 weeks)+6.9+6.1
STEP 5 (n=304)15SC semaglutide 2.4 mg PlaceboResults pendingResults pendingResults pending
  • NR means the value was not recorded in the trial results.

  • Results for STEP 515 are pending at the time of writing this review.

  • SC, subcutaneous; STEP, Semaglutide Treatment Effect in People with Obesity.